Teamwork Financial Advisors LLC Has $2.21 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Teamwork Financial Advisors LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 616.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 31,883 shares of the company's stock after purchasing an additional 27,431 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $2,214,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. M. Kulyk & Associates LLC increased its position in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares in the last quarter. Center for Financial Planning Inc. grew its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the last quarter. Tradewinds Capital Management LLC grew its holdings in Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock worth $429,000 after acquiring an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC raised its position in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock worth $1,987,000 after acquiring an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC boosted its stake in Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after acquiring an additional 126 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $128.00.

Novo Nordisk A/S Stock Up 0.7%

NVO stock traded up $0.53 during mid-day trading on Thursday, reaching $72.57. The company had a trading volume of 5,088,580 shares, compared to its average volume of 6,858,486. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a 50 day simple moving average of $65.67 and a two-hundred day simple moving average of $81.09. The company has a market capitalization of $325.64 billion, a price-to-earnings ratio of 22.06, a PEG ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.